学术论文： |
发表文章 1. Luo HG#, Liu LP, Liu XP, Xie YD, Huang X, Yang M, Shao C* and Li D*. Interleukin-33 (IL-33) promotes DNA damage-resistance in lung cancer. Cell Death and Disease, (2025) 16:274. (IF=8.1) 2. Zhuang D#, Kang JS#, Luo HG, Tian Y, Liu XP and Shao C*. ARv7 promotes the escape of prostate cancer cells from androgen deprivation therapy-induced senescence by mediating the SKP2/p27 axis. BMC Biology, (2025) 23:66. (IF=4.4) 3. Zhao JQ#, Liu XP, Zhang TH, Luo HG, Zhang J* and Shao C*. Capsaicin functions as an androgen receptor antagonist inhibiting the growth of prostate cancer in cellular and mice models. Food Bioscience, 69 (2025) 107000. (IF=4.8) 4. Ren L#, Luo HG#, Zhao JQ, Huang SQ, Zhang J* and Shao C*. An integrated in vitro/in silico approach to assess the anti-androgenic potency of isobavachin. Food and Chemical Toxicology, 176 (2023) 113764. (IF=4.3) 5. Luo HG#, Liu YN#, Li Y, Zhang CK, Yu BB and Shao C*. Androgen receptor splicing variant 7 (ARv7) promotes DNA damage response in prostate cancer cells. FASEB Journal, 2022; Sep; 36(9): e22495. (IF=5.834) 6. Yu BB#, Liu YN, Luo HG, Fu JY, Li Y, Shao C*. Androgen receptor splicing variant 7(ARV7) inhibits docetaxel sensitivity by inactivating the spindle assembly checkpoint. Journal of Biological Chemistry, 2021:100276. (IF=5.157) 7. Shao C#, Yu BB and Liu YN*. Androgen receptor splicing variant 7: Beyond being a constitutively active variant. Life Sciences, 2019, 234:116768. (IF=3.647) 8. Shao C#, Chien SJ, Farah E, Li Z, Ahmad N, Liu X*. Plk1 phosphorylation of Numb leads to impaired DNA damage response. Oncogene, 2018,37:810-820. (IF=6.634) 9. Shao C#, Li Z, Ahmad N, Liu X*. Regulation of PTEN degradation and NEDD4-1 E3 ligase activity by Numb. Cell Cycle, 2017;16(10):957-967(IF=3.304) 10. Li Z#, Shao C, Kong YF, Carlock C, Ahmad N, Liu X*. DNA damage response-independent role for MDC1 in maintaining genomic stability. Molecular and cellular biology, 2017,;37(9): e00595-16. (IF=4.398) 11. Shao C#, Ahmad N, Hodges K, Kuang SH, Ratliff T, Liu X*, Inhibition of polo-like kinase 1(Plk1) enhances the antineoplastic activity of metformin in prostate cancer, Journal of Biological Chemistry,2015.1.23; 290(4):2024-33. (IF=4.258) 12. Zhang Z#, Hou XZ, Shao C, Li JJ, Cheng JX, Kuang SH, Ahmad N, Ratliff T, Liu X*. Plk1 inhibition enhances the efficacy of androgen signaling blockade in castration-resistant prostate cancer. Cancer Research, 2014;74(22):6635-47. (IF=13.312) |
